In particular, antibodies targeting the checkpoints CTLA-4, PD-1, and PD-L1 are effective against a variety of cancer types, establishing the principle that blocking inhibitory immune pathways can promote an anti-tumor immune response and lead to clinical benefit3. The gene discussed is CTLA4; the disease is neoplasm.